Trial Profile
Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse Large B Cell Lymphoma (DLBCL): The AvR-CHOP Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 06 Feb 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cyclophosphamide; Doxorubicin; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Acronyms AvR-CHOP
- 18 Jul 2022 Planned primary completion date changed from 1 Feb 2021 to 1 Sep 2022.
- 18 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2020 Results (n=28) presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology